5th World Congress on Cancer Therapy
Holy Stone Healthcare Co., Ltd., Taiwan
Title: Hyaluronic Acid (HA) drug conjugates for targeted delivery of anticancer drugs: CA102N, A novel Hyaluronic acid conjugated drug against colorectal cancer
Biography: Eskouhie Tchaparian
This talk will address recent trends in targeted anticancer drug delivery systems with a focus on Hyaluronic Acid (HA) drug conjugate, a linear polysaccharide, for selective and targeted transport of anticancer therapeutics. It will also discuss the advantages of using this approach to deliver drugs at desired locations. Concept, design, and applications will be emphasized. A specifi c example CA102N, a Nimuselide (COX2 inhibitor) derivative (HA) conjugate, will be presented. CA102N is currently in preclinical development as a new anticancer agent against colorectal cancer. Th e antitumor activity, in vitro (cell based) and in vivo (xenograft s mice), of CA102N will be communicated. In addition, some hightlights on the potential of its mechanism of action (MOA) will be elucidated. A brief description of the preclinical safety of CA102N and the overall safety profi le of HA drug conjugates will be evaluated as well.